Skip to main content
LeonaBio logo

LeonaBio

Bothell, Washington, United StatesSee on the mapFounded 2011

  • Series B
  • ALS

LeonaBio is a biotechnology company developing novel therapeutics for diseases with high unmet medical needs, including neurological diseases such as amyotrophic lateral sclerosis (ALS) and treatment-resistant metastatic breast cancer. Its research emphasizes neuronal health and therapies intended to restore and maintain cellular connections.

Raised
$807M
Jun 2020
Series B
Investors
35
Founded
2011
Employees
51–200

reccy insights

Recent highlights

That financing followed a $103.5 million post-IPO equity round dated Jan 20, 2021. The company’s stated research focus spans neurological disease and oncology, including ALS and treatment-resistant metastatic breast cancer. Its therapeutic approach emphasizes neuronal health and restoring cellular connections; the structured company description also identifies ATH-1020 as a candidate designed to enhance the neurotrophic HGF system. The company-name information is inconsistent: LeonaBio is associated with the Bothell business identity, while another company name appears in company details. The financing and research details should therefore be read with that identity discrepancy in mind.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes LeonaBio distinct

  1. 01Pursues therapies for high-unmet-need conditions across neurological disease and oncology.
  2. 02Centers its therapeutic research on neuronal health and restoring cellular connections.
  3. 03Identifies ALS and treatment-resistant metastatic breast cancer among its areas of focus.
  4. 04Describes a patient-centered, collaborative culture emphasizing inclusion, integrity, and innovation.

Technology & products

  • ATH-1020

    A drug candidate designed to enhance the neurotrophic HGF system to support neuronal health and function.

  • Research focused on neuronal health and restoring cellular connections.
  • ATH-1020 is designed to enhance the neurotrophic HGF system.
  • Exploration of early compounds directed at novel targets for clinical applications.

Research roots1

Labs and research groups this company came from or works with.

  • Washington State UniversityPullman, United States · No page yet
    Licence
Academic data: Carter Sciences

Funding

$807M disclosed
Latest valuation $9.9 million35 investors

Investors11

Also backed by
  • TCGX
  • Bruce Montgomery
  • Michael Montgomery
  • Ditch Plains Capital Management

About LeonaBio

Products
ATH-1020
Leadership
Leen KawasLewis RumplerJoseph Harding
Focus areas
Biotechnology, therapeutics, pharmaceuticals, neurology, oncology, neuroscience, drug discovery, ALS
Headquarters
Bothell, Washington, United States
Founded
2011
Employees
51–200
Status
Active · public company